Emerald BioStructures
Emerald BioStructures, UCB Extend Deal for Drug Target Identification
NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB have extended a collaboration aimed at identifying multiple targets in the drug discovery process, Emerald announced on Thursday.
Emerald BioStructures, UCB Expand Drug Discovery Collaboration
The firms achieved a second milestone in their drug discovery pact, which utilizes Emerald's X-ray crystallography platform.
Movers & Shakers: Oct 29, 2010
Premium
John Hunt, John McCall, John Mulligan, Lynn Silver
The agreement with NEC, which has purchased an equity stake in the company, is part of its plan to expand beyond its traditional focus on biomarker discovery and diagnostics development to become a "health information company" that can "provide actionable medical information to patients, physicians, and researchers," said an official.
Emerald BioStructures, SomaLogic in DNA Aptamer Alliance
The firms are building on a collaboration from last year, under which they unraveled the first X-ray structure of a DNA aptamer bound to its protein target.